Zhangda Hospital Southeast University
Welcome,         Profile    Billing    Logout  
 18 Trials 
14 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wang, Hong
HER2CLIMB-02, NCT03975647 / 2019-005017-39: A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Jan 2024 - Dec 2024: From HER2CLIMB-02 trial for breast cancer
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of HER2CLIMB-02 trial in combination with Kadcyla for breast cancer
Active, not recruiting
3
466
Europe, Canada, Japan, US, RoW
tucatinib, ONT-380, placebo, T-DM1, Kadcyla
Seagen Inc., Seagen Inc., Seattle Genetics, Inc., Seagen Inc
HER2-positive Breast Cancer
06/23
10/27
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
SURPASS-CN-INS, NCT05691712: A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes

Completed
3
257
RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases
07/24
07/24
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting
3
3000
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Overweight or Obesity
07/25
07/27
NCT05520177: A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss

Recruiting
3
350
RoW
601 1.25mg, 601, ranibizumab 0.5mg, Lucentis
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Branch Retinal Vein Occlusion
12/25
12/25
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT04398940: A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer

Recruiting
2
71
RoW
TQ-B3139
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non Small Cell Lung Cancer
01/22
10/22
NCT06212297: Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy

Recruiting
1/2
9
RoW
LX101
Innostellar Biotherapeutics Co.,Ltd
Inherited Retinal Dystrophy
09/24
03/29
NCT04458389: A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas

Recruiting
1/2
268
RoW
TY101
Tayu Huaxia Biotech Medical Group Co., Ltd.
Locally Advanced /Metastatic Solid Tumors, Relapsed or Refractory Lymphomas
06/24
07/25
NCT05715333: Study of CM326 Injection in Healthy Subjects

Completed
1
46
RoW
CM326, Placebo
Keymed Biosciences Co.Ltd
Healthy
10/23
10/23
NCT06432738: ZL-82 Double-blind Clinical Trial

Recruiting
1
40
RoW
ZL-82, 600mg ZL-82, 50mg ZL-82, 100mg ZL-82, 200mg ZL-82, ZL-82 placebo, 600mg ZL-82 placebo, 50mg ZL-82 placebo, 100mg ZL-82 placebo, 200mg ZL-82 placebo
Chengdu Zenitar Biomedical Technology Co., Ltd
Healthy Person
08/24
12/24
NCT05702450: Study to Evaluate Pharmacokinetics, Safety and Efficacy of CM310

Completed
1
240
RoW
CM310
Keymed Biosciences Co.Ltd
Healthy
07/23
07/23
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System

Not yet recruiting
N/A
2150
RoW
Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy
Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Heart Disease
01/26
01/28

Download Options